The Immunoregulatory Role of Alveolar Macrophages in Chronic Beryllium Disease

Trial Objective

Chronic beryllium disease (CBD) is caused by inhaling beryllium dust and fumes into the lungs. People with exposure can develop a response to beryllium similar to an allergy which can lead to scars in the lungs and breathing problems.

The Immunoregulatory Role of Alveolar Macrophages in Chronic Beryllium Disease

The goal of this study is to understand how certain white blood cells called macrophages function in the development of CBD. By collecting lung and blood samples from healthy adults, our researchers can learn more about the cells involved in the development of scarring lung diseases and ultimately target new treatment therapies.

Enrollment

This trial is active and currently recruiting.

How to Participate

For more information, contact Peggy Mroz at 303.398.1730 or complete the form below.

Who Can Participate

Healthy, nonsmoking adults with no prior history of respiratory or autoimmune disease who are able to undergo a blood draw and a bronchoscopy.


Estimated Time Commitment

5 hours over 2 visits

During the first visit, participants give consent and receive physical exam. Second visit includes bronchoalveolar lavage and blood draw. The second visit will last approximately four hours.

Trial Location

National Jewish Main Campus, Denver, CO

Compensation

Provided

Trial Sponsors

National Institutes of Health

Age

18-80


Gender

Any Gender

Co-Investigators


Request More Information

*
*
*
*